Evidence map›Paper›PMID 38389647›Full record

ArticleCureus2024

Metabolic and Epigenetic Reprogramming in a Case of Nuclear Protein in Testis (NUT) Carcinoma of the Retroperitoneum.

Mika Serizawa, Kaho Serizawa, Kenta Masui, Makoto Toguchi, Kumiko Murakami, Tomoko Yamamoto, Yoji Nagashima, Toshio Takagi, Atsushi Kurata

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mika SerizawaDepartment of Pathology, Tokyo Women's Medical University, Tokyo, JPN.
Kaho SerizawaDepartment of Pathology, Tokyo Women's Medical University, Tokyo, JPN.
Kenta MasuiDepartment of Pathology, Tokyo Women's Medical University, Tokyo, JPN.
Makoto ToguchiDepartment of Urology, Tokyo Women's Medical University Hospital, Tokyo, JPN.
Kumiko MurakamiDepartment of Pathology, Tokyo Women's Medical University, Tokyo, JPN.
Tomoko YamamotoDepartment of Surgical Pathology, Tokyo Women's Medical University Hospital, Tokyo, JPN.
Yoji NagashimaDepartment of Surgical Pathology, Tokyo Women's Medical University Hospital, Tokyo, JPN.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University Hospital, Tokyo, JPN.
Atsushi KurataDepartment of Pathology, Tokyo Women's Medical University, Tokyo, JPN.
Tokyo Women's Medical University Hospital · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear protein in testis (NUT) carcinoma is a rare but highly aggressive carcinoma, driven by genetic rearrangement of the NUT midline carcinoma family member 1 (

Indexed as

brd4-nutepigeneticsmetabolic reprogrammingnut carcinomaretroperitoneum

Identifiers

PMID38389647
PMCPMC10883765
OpenAlexW4391151618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.